Patients randomized  
n=60

Telavancin  
n=30

- n=1

- n=29

Positive follow-up blood culture=8  
Absence of defervescence=3  
Non-removable hardware=2  
>72 h prior antibiotic therapy=2  
SAB not documented=2  
Metastatic infection ≤Day 5=1  
Significant valvular disease=3

- n=15

Response not determined at TOC=4  
Cure with <12 days of therapy or failure with <3 days of therapy=3  
Concomitant potentially effective antibacterial therapy prior to TOC=2

Clinically evaluable patients  
n=17

Standard therapy  
n=30

Did not receive study medication  
n=2

- n=1

All-treated patients  
n=58

Positive follow-up blood culture=8  
Absence of defervescence=3  
>72 h prior antibiotic therapy=2  
SAB not documented=2  
Metastatic infection ≤Day 5=1  
Permanent catheter=1

- n=27

Continuation criteria not met or continued participation deemed inappropriate by Clinical Event Committee  
n=27

Patients excluded from analysis  
n=14

Response not determined at TOC=4  
Cure with <12 days of therapy or failure with <3 days of therapy=3  
Concomitant potentially effective antibacterial therapy prior to TOC=2  
TOC outside study window=2

Clinically evaluable patients  
n=17

Standard therapy  
n=9